Cargando…

SUN-512 Denosumab Improves Trabecular but Not Cortical Bone Osteoporosis in a Patient with Refractory Primary Hyperparathyroidism

Background: Primary hyperparathyroidism is a disorder of parathyroid glands in which one or more of these glands is/are overactive. As a result, the overactive gland releases too much parathyroid hormone (PTH) which increases serum calcium levels from thinning of the bones. Osteoporosis occurs in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhassan, Sharifa, Jaume, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552689/ http://dx.doi.org/10.1210/js.2019-SUN-512

Ejemplares similares

SUN-514 Severe Hypophosphatemia and Worsening Secondary Hyperparathyroidism Following Treatment with Denosumab
por: Adepoju, Yewande, et al.
Publicado: (2019)

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)

Parathyromatosis Recurrent Hyperparathyroidism and Refractory Hypercalcemia Successfully Managed With Addition of Denosumab: A Case Report
por: Alhammad, Zahrah Abbas, et al.
Publicado: (2021)

SAT-512 Severe Hypocalcemia Presenting as Status Epilepticus after Denosumab Use in Metastatic Prostate Cancer
por: Saeed, Zeb, et al.
Publicado: (2019)

SAT-405 Trabecular Bone Score (TBS) in Primary Hyperparathyroidism (PHP): A Useful Tool?
por: Santos, Lívia Marcela, et al.
Publicado: (2020)

SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

SUN-376 A Quality Improvement Project on Identification and Management of Primary Hyperparathyroidism in Patients Who Present with Osteoporosis to Reduce Morbidity from Bone Disease
por: Hatta, Sharifah Faradila Wan Muhamad, et al.
Publicado: (2020)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

SUN-490 Enigmatic Presentations Of Hyperparathyroidism
por: NAGAPRIYA, VELLALACHERUVU, et al.
Publicado: (2019)

SAT-395 Correlations Between Biochemical Parameters and Trabecular Bone Score (TBS) in Primary Hyperparathyroidism (PHP) Patients
por: Santos, Lívia Marcela, et al.
Publicado: (2020)

ODP084 Denosumab as a therapuetic modality in management of primary hyperparathyroidism induced severe hypercalcemia
por: Mangaraj, Swayamsidha, et al.
Publicado: (2022)

SUN-396 Denosumab Preserves Bone Mineral Density at the Knee in Persons with Subacute Spinal Cord Injury
por: Bauman, William Alan, et al.
Publicado: (2020)

SUN-368 Wnt Inhibition Decreases Trabecular Bone in a Mouse Model of Fibrous Dysplasia
por: Lung, Hsuan, et al.
Publicado: (2020)

SUN-513 Parathyromatosis: A Case of Stubborn Hypercalcemia Treated with Denosumab
por: Ventura, Kenilia, et al.
Publicado: (2019)

SUN-496 A Perioperative Risk For Exacerbation of Hypercalcemia in Primary Hyperparathyroidism
por: Tezuka, Yuta, et al.
Publicado: (2019)

SUN-526 Prevalence of Hyperparathyroidism in X-Linked Hypophosphatemia
por: DeLacey, Sean, et al.
Publicado: (2019)

SUN-500 Primary Hyperparathyroidism as Initial Presentation of Stage IV Breast Cancer
por: Magdaleno, Angela, et al.
Publicado: (2019)

SUN-355 Associations of Trabecular Bone Score and Bone Mineral Density with Cardiorespiratory Fitness and Body Composition in Men with and Without Paraplegia
por: Usuga, Daniela, et al.
Publicado: (2020)

SUN-492 Unresolved Hyperparathyroidism Due To Mediastinal Parathyroid Adenoma
por: Brown, Isaiah, et al.
Publicado: (2019)

SAT228 Denosumab Associated Severe Hypocalcemia Due To Vitamin D Deficiency In A Patient With Undiagnosed Primary Hyperparathyroidism
por: Reddy Bendaram, Snigdha, et al.
Publicado: (2023)

SUN-493 Spontaneous Remission of Primary Hyperparathyroidism Presenting as Acute Chest and Neck Pain
por: Liao, Huijuan, et al.
Publicado: (2019)

SUN-494 Multiple Ectopic Parathyroid Foci: An Unexpected Finding Leading to Primary Hyperparathyroidism
por: Yazdanie, Noor, et al.
Publicado: (2019)

MON-LB085 Blurred Vision and Hypocalcemia after Denosumab Injection in a Patient with Tertiary Hyperparathyroidism
por: Lim, Jayoung, et al.
Publicado: (2019)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

SUN-503 Hyperparathyroidism and Turner Syndrome: A Rare, Overlooked Association?
por: de Albuquerque Albuquerque, Edoarda, et al.
Publicado: (2019)

SUN-509 A Challenging Case of Symptomatic Primary Hyperparathyroidism during Pregnancy Treated with Cinacalcet
por: Rodriguez, Aleida, et al.
Publicado: (2019)

SUN-504 Association of Primary Hyperparathyroidism and Humoral Hypercalcemia of Malignancy in a Patient with Metastatic Endocervical Adenocarcinoma
por: de la Portilla, Lori, et al.
Publicado: (2019)

MON-335 Bisphosphonate and Denosumab Refractory Hypercalcemia of Malignancy: What Else Is at Play?
por: Patel, Reshma, et al.
Publicado: (2020)

SUN-LB085 Complicated Hungry Bone Syndrome Due to Tertiary Hyperparathyroidism in a Patient with Kidney Transplant: A Case to Remember
por: Jimenez-Zuluaga, Jose, et al.
Publicado: (2019)

Severe Refractory Hypocalcemia After Administering Zoledronic Acid for Osteoporotic Fracture in Primary Hyperparathyroidism That Is Complicated Into Hungry Bone Syndrome: A Case Report
por: Alhamdan, Ali Saleh, et al.
Publicado: (2021)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

FRI690 Should Treatment For Osteoporosis Be Started In Patients With Primary Hyperparathyroidism Within The First Year After Parathyroidectomy?
por: Swe, Khine Mon, et al.
Publicado: (2023)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

SUN-366 Neonatal Severe Hyperparathyroidism: Extreme Hypercalcemia as a Robust Marker for Homozygous Dosage of Pathogenic CASR Variants
por: Marx, Stephen J, et al.
Publicado: (2020)

Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
por: Santos, Lívia Marcela, et al.
Publicado: (2021)

OR01-5 Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study
por: Ibrahim, Quazi, et al.
Publicado: (2022)

Single Dose of Denosumab Effective for Management of Bisphosphonate-Refractory Hypercalcemia of Malignancy Related to Non-Small Cell Lung Cancer
por: Dinh, Kathryn, et al.
Publicado: (2021)

THU415 Trabecular Bone Score In Hospitalized Patients With Heart Failure
por: Bandeira, Francisco, et al.
Publicado: (2023)

Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study
por: Khan, Aliya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eeb2uiq0k5itsb1fo7tqjdhl6r